N30 Pharmaceuticals begins patient treatment in Phase 1b/2a cystic fibrosis study

Ascending doses of N6022 will be evaluated in the multi center, double-blind study that is being conducted in collaboration with the Cystic Fibrosis Foundation’s Therapeutics Development Network (TDN).

N30 Pharma president and chief executive officer Charles Scoggin said, "We are indebted to the cystic fibrosis clinicians and nurses who have given us such valuable advice, to the members of the TDN who have been instrumental in getting this first trial started, and to the patients who will be volunteering for participation."

Evaluation of the safety of repeat doses of N6022 is the primary objective of the randomised, placebo-controlled study.

The evaluation of N6022 serum levels, lung function, and other markers of disease activity in CF include the secondary and exploratory objectives of the study.

N6022 works by conserving endogenous, signalling molecule S-nitrosoglutathione (GSNO), that is believed to reduce in CF patients.